Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O15530
UPID:
PDPK1_HUMAN
Alternative names:
-
Alternative UPACC:
O15530; H0Y4Z0; Q59EH6; Q6FI20; Q8IV52; Q9BRD5
Background:
3-phosphoinositide-dependent protein kinase 1 (PDK1) is a serine/threonine kinase pivotal in cellular signaling. It phosphorylates and activates AGC family kinases, including AKT, RPS6KB1, and PRKACA, influencing cell proliferation, survival, and metabolism. PDK1's role extends to modulating TGF-beta signaling, adipocyte differentiation, NF-kappa-B pathway activation, and vascular endothelial cell motility. It also impacts cardiac function, thymocyte development, and macrophage responses.
Therapeutic significance:
Understanding the role of 3-phosphoinositide-dependent protein kinase 1 could open doors to potential therapeutic strategies.